Rhumbline Advisers Cin Cor Pharma, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$10.75 - $29.84 $51,718 - $143,560
4,811 Added 17.42%
32,427 $399,000
Q3 2022

Nov 10, 2022
BUY
$19.9 - $38.94 $169,368 - $331,418
8,511 Added 44.55%
27,616 $906,000
Q2 2022

Aug 11, 2022
BUY
$13.67 - $25.74 $261,165 - $491,762
19,105 New
19,105 $360,000

Others Institutions Holding CINC

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About CinCor Pharma, Inc.

CINC Quotes by TradingView
  • Ticker CINC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,764,300
  • Description
  • CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial...
More about CINC
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email